"Treatment IND for Pediatric Zidovudine"

Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

"Treatment IND for Pediatric Zidovudine"

Journal of the American Medical Association (12/15/89) Vol. 262,

Abstract: FDA has approved the distribution of zindovudine (also known as AZT) strawberry-flavored syrup under a Treatment IND forchildren between the ages of 3 months and 13 years who have AIDS or are suffering from symptoms of advanced infection with the AIDS virus. Data indicate that the drug may prolong survival andrelieve severe AIDS symptoms in children as it does in adults. Zidovudine will be distributed to eligible children under a Treatment IND protocol sponsored by the Burroughs Wellcome Co. (the drug's manufacturer), with medical and technical assistance by the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health.

891215
AD892745

Copyright © 1989 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.